CA3231660A1 - Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof - Google Patents
Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof Download PDFInfo
- Publication number
- CA3231660A1 CA3231660A1 CA3231660A CA3231660A CA3231660A1 CA 3231660 A1 CA3231660 A1 CA 3231660A1 CA 3231660 A CA3231660 A CA 3231660A CA 3231660 A CA3231660 A CA 3231660A CA 3231660 A1 CA3231660 A1 CA 3231660A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- solvate
- pharmaceutically acceptable
- acceptable salt
- tautomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163245718P | 2021-09-17 | 2021-09-17 | |
| US63/245,718 | 2021-09-17 | ||
| PCT/US2022/043660 WO2023043923A1 (en) | 2021-09-17 | 2022-09-15 | Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3231660A1 true CA3231660A1 (en) | 2023-03-23 |
Family
ID=85603496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3231660A Pending CA3231660A1 (en) | 2021-09-17 | 2022-09-15 | Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250002486A1 (https=) |
| EP (1) | EP4401728A4 (https=) |
| JP (1) | JP2024534420A (https=) |
| KR (1) | KR20240101555A (https=) |
| CN (1) | CN118434417A (https=) |
| AU (1) | AU2022345092A1 (https=) |
| CA (1) | CA3231660A1 (https=) |
| IL (1) | IL311458A (https=) |
| MX (1) | MX2024003258A (https=) |
| TW (1) | TW202328121A (https=) |
| WO (1) | WO2023043923A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2021325905A1 (en) | 2020-08-12 | 2023-04-13 | Boundless Bio, Inc. | Replication stress pathway agent compositions and methods for treating cancer |
| JP2025531147A (ja) * | 2022-09-13 | 2025-09-19 | バウンドレス バイオ，インク． | 環状スルホンアミドリボヌクレオチドレダクターゼ（ｒｎｒ）阻害剤およびその使用 |
| WO2025049814A2 (en) * | 2023-09-01 | 2025-03-06 | Boundless Bio, Inc. | Ribonucleotide reductase (rnr) compositions and methods of use |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3466934T (pt) * | 2016-05-31 | 2024-04-30 | Taiho Pharmaceutical Co Ltd | Compostos de sulfonamida ou seus sais como inibidores da ribonucleótido-redutase para o tratamento de cancro |
| US20200405697A1 (en) * | 2017-11-29 | 2020-12-31 | Taiho Pharmaceutical Co., Ltd. | Antitumor Agent |
| MX2020005478A (es) * | 2017-11-29 | 2020-08-27 | Taiho Pharmaceutical Co Ltd | Compuestos de sulfonamida y usos de los mismos. |
| US20220226291A1 (en) * | 2019-05-29 | 2022-07-21 | Taiho Pharmaceutical Co., Ltd. | Combination Treatment of Cancer Using Sulfonamide Compound and Immune Regulator |
| US20240158383A1 (en) * | 2021-03-02 | 2024-05-16 | Boundless Bio, Inc. | Ribonucleotide reductase (rnr) inhibitors and uses thereof |
-
2022
- 2022-09-15 IL IL311458A patent/IL311458A/en unknown
- 2022-09-15 AU AU2022345092A patent/AU2022345092A1/en active Pending
- 2022-09-15 JP JP2024516798A patent/JP2024534420A/ja active Pending
- 2022-09-15 EP EP22870692.5A patent/EP4401728A4/en active Pending
- 2022-09-15 WO PCT/US2022/043660 patent/WO2023043923A1/en not_active Ceased
- 2022-09-15 CA CA3231660A patent/CA3231660A1/en active Pending
- 2022-09-15 US US18/692,503 patent/US20250002486A1/en active Pending
- 2022-09-15 TW TW111134951A patent/TW202328121A/zh unknown
- 2022-09-15 KR KR1020247012612A patent/KR20240101555A/ko active Pending
- 2022-09-15 CN CN202280075394.XA patent/CN118434417A/zh active Pending
- 2022-09-15 MX MX2024003258A patent/MX2024003258A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022345092A1 (en) | 2024-04-04 |
| EP4401728A4 (en) | 2025-08-06 |
| MX2024003258A (es) | 2024-04-05 |
| EP4401728A1 (en) | 2024-07-24 |
| WO2023043923A1 (en) | 2023-03-23 |
| JP2024534420A (ja) | 2024-09-20 |
| IL311458A (en) | 2024-05-01 |
| KR20240101555A (ko) | 2024-07-02 |
| CN118434417A (zh) | 2024-08-02 |
| TW202328121A (zh) | 2023-07-16 |
| US20250002486A1 (en) | 2025-01-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3219348A1 (en) | Checkpoint kinase 1 (chk1) inhibitors and uses thereof | |
| CA3231660A1 (en) | Cyclic sulfonamide ribonucleotide reductase (rnr) inhibitors and uses thereof | |
| JP2025522294A (ja) | ピリジンチェックポイントキナーゼ１（ｃｈｋ１）阻害剤及びその使用 | |
| US9346795B2 (en) | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | |
| AU2022307534B2 (en) | Pyridinone mk2 inhibitors and uses thereof | |
| EA021126B1 (ru) | Замещенные изохинолиноны и хинализолиноны | |
| EA015952B1 (ru) | 2-пиридинкарбоксамидные производные в качестве модуляторов натриевых каналов | |
| PT2021330E (pt) | Moduladores benzimidazoles de vr1 | |
| CA3238655A1 (en) | Thiophene ulk1/2 inhibitors and their use thereof | |
| TW200827340A (en) | Chemical compounds | |
| JP2022530866A (ja) | Ｐｒｃ２阻害剤としてのナフチリジン誘導体 | |
| JP6713000B2 (ja) | 抗腫瘍活性を有する化合物 | |
| CA3182873A1 (en) | Sulphonamide compounds | |
| WO2022187200A1 (en) | Ribonucleotide reductase (rnr) inhibitors and uses thereof | |
| EP4402134A1 (en) | Sulfamide ribonucleotide reductase (rnr) inhibitors and uses thereof | |
| TW202421160A (zh) | 環狀磺醯胺核糖核苷酸還原酶(rnr)抑制劑及其用途 | |
| EA051928B1 (ru) | Пиридиновые ингибиторы киназы 1 контрольной точки (chk1) и их применение | |
| TW200536834A (en) | New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors | |
| NZ754629B2 (en) | Novel bicyclic bromodomain inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240906 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240906 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240906 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241007 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W200 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST OR RESPONSE SUBMITTED ONLINE Effective date: 20241203 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260302 |